Hyperuricemia Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Hyperuricemia Pipeline

LAS VEGAS, NV, UNITED STATES, February 13, 2025 /EINPresswire.com/ -- DelveInsight’s, “Hyperuricemia Pipeline Insight” report provides comprehensive insights about 12+ companies and 15+ pipeline drugs in Hyperuricemia pipeline landscape. It covers the Hyperuricemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hyperuricemia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Hyperuricemia pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Hyperuricemia Pipeline Report to explore emerging therapies, key Hyperuricemia Companies, and future Hyperuricemia treatment landscapes @ Hyperuricemia Pipeline Outlook Report

Key Takeaways from the Hyperuricemia Pipeline Report
• In February 2025:- Arthrosi Therapeutics:- This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months.
• In January 2025:- Urica Therapeutics Inc.: A open label multi-center 3-period multidose, PK/PD and drug-drug interaction (DDI) study to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of 7 days of treatment with two doses of dotinurad monotherapy, and to evaluate the effect of dotinurad, as monotherapy and in combination with allopurinol, versus allopurinol monotherapy, on the PK of each, and to assess the additive PD effects on serum uric acid and urinary urate excretion in U.S. patients with gout and hyperuricemia
• DelveInsight’s Hyperuricemia pipeline report depicts a robust space with 12+ active players working to develop 15+ pipeline therapies for Hyperuricemia treatment.
• The leading Hyperuricemia Companies such as Shanton Pharma, LG Chem, Sunshine Lake Pharma, InventisBio, Jiangsu Atom Bioscience and Pharmaceutical, Nippon Chemiphar, and others.
• Promising Hyperuricemia Therapies such as D-0120, Benzbromaron, SHR4640, FYU-981, Topiroxostat, and others.

Discover how the Hyperuricemia treatment paradigm is evolving. Access DelveInsight’s in-depth Hyperuricemia Pipeline Analysis for a closer look at promising breakthroughs @ Hyperuricemia Clinical Trials and Studies

Hyperuricemia Emerging Drugs
• ABP-671: Jiangsu Atom Bioscience
ABP-671, developed by Jiangsu Atom Bioscience and Pharmaceutical, is a small molecule under clinical development for treating gout associated with hyperuricemia. This drug is administered orally and acts by targeting the urate transporter 1 (URAT1) protein involved in uric acid reabsorption by the kidneys. ABP-671's mechanism of action involves inhibiting URAT1, which helps in reducing uric acid levels significantly and safely compared to existing gout treatments. This drug has shown promising results in clinical trials, demonstrating efficacy in maintaining serum uric acid levels within the recommended range for gout patients. Currently, the drug is in Phase III stage of its clinical trial for the treatment of hyperuricemia.

• LR19074: LG Life Sciences
LR19074 is a novel non-purine selective inhibitor of Xanthine Oxidase (XO). XO is needed to successively oxidize both hypoxanthine and xanthine to uric acid. Hence, this agent reduces uric acid concentrations in serum by inhibiting the production of uric acid by XO inhibition. LC350189 has the potential to address the unmet clinical needs for safety and efficacy in gout treatment. LC350189 showed good systemic exposures and sUA lowering effects with no significant safety concerns in Korean and the U.S. healthy volunteers. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Hyperuricemia.

• NC-2500: Nippon Chemiphar
NC-2500 is a novel advanced xanthine oxidoreductase (XOR) inhibitor, having potential to reduce the risk of gout flare, one of major issues of current treatments for gout, and make a difference in gout treatment. Currently, the drug is in Phase I stage of its clinical trial for the treatment of hyperuricemia.

The Hyperuricemia pipeline report provides insights into
• The report provides detailed insights about Hyperuricemia companies that are developing therapies for the treatment of Hyperuricemia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hyperuricemia Treatment.
• Hyperuricemia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Hyperuricemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hyperuricemia market.

Get a detailed analysis of the latest innovations in the Hyperuricemia pipeline. Explore DelveInsight’s expert-driven report today! @ Hyperuricemia Unmet Needs

Hyperuricemia Companies
Shanton Pharma, LG Chem, Sunshine Lake Pharma, InventisBio, Jiangsu Atom Bioscience and Pharmaceutical, Nippon Chemiphar, and others.

Hyperuricemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Hyperuricemia Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming Hyperuricemia Therapies and key Hyperuricemia Developments @ Hyperuricemia Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/hyperuricemia-pipeline-insight?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Hyperuricemia Pipeline Report
• Coverage- Global
• Hyperuricemia Companies- Shanton Pharma, LG Chem, Sunshine Lake Pharma, InventisBio, Jiangsu Atom Bioscience and Pharmaceutical, Nippon Chemiphar, and others.
• Hyperuricemia Therapies- D-0120, Benzbromaron, SHR4640, FYU-981, Topiroxostat, and others.
• Hyperuricemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Hyperuricemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Hyperuricemia drug development? Find out in DelveInsight’s exclusive Hyperuricemia Pipeline Report—access it now! @ Hyperuricemia Emerging Drugs and Major Companies- https://www.delveinsight.com/sample-request/hyperuricemia-pipeline-insight?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Hyperuricemia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Hyperuricemia – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. ABP-671: Jiangsu Atom Bioscience
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. LR19074: LG Life Sciences
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. NC-2500: Nippon Chemiphar
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Hyperuricemia Key Companies
21. Hyperuricemia Key Products
22. Hyperuricemia - Unmet Needs
23. Hyperuricemia - Market Drivers and Barriers
24. Hyperuricemia - Future Perspectives and Conclusion
25. Hyperuricemia Analyst Views
26. Hyperuricemia Key Companies
27. Appendix

List of Top Selling Market Research Reports in 2025

Athlete's Foot Market- https://www.delveinsight.com/report-store/athletes-foot-market
Tuberculosis Market- https://www.delveinsight.com/report-store/tuberculosis-market
Wound Healing Devices Market- https://www.delveinsight.com/report-store/wound-healing-devices-market
Attention Deficit Hyperactivity Disorder Market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Complex Regional Pain Syndrome Market- https://www.delveinsight.com/report-store/complex-regional-pain-syndrome-crps-market
Coronary Microvascular Dysfunction Market- https://www.delveinsight.com/report-store/coronary-microvascular-dysfunction-market
Diabetes Insipidus Market- https://www.delveinsight.com/report-store/diabetes-insipidus-market
HDAC Inhibitors Market- https://www.delveinsight.com/report-store/hdac-inhibitor-pipeline-insight
Healthcare Competitive Benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Heart Failure Market- https://www.delveinsight.com/report-store/congestive-heart-failure-market
Hyperphosphatemia Market- https://www.delveinsight.com/report-store/hyperphosphatemia-market
Immune Checkpoints Activators Market- https://www.delveinsight.com/report-store/immune-checkpoints-activators
Japan Healthcare Outlook Market- https://www.delveinsight.com/report-store/japan-healthcare-outlook-report
Joint Reconstruction Devices Market- https://www.delveinsight.com/report-store/joint-reconstruction-devices-market
Mantle Cell Lymphoma Market- https://www.delveinsight.com/report-store/mantle-cell-lymphoma-market
Methicillin-resistant Staphylococcus Aureus Infection Market- https://www.delveinsight.com/report-store/methicillin-resistant-staphylococcus-aureus-mrsa-market
Mouth Neoplasms Market- https://www.delveinsight.com/report-store/mouth-neoplasms-market
Myocardial Infarction Market- https://www.delveinsight.com/report-store/myocardial-infarction-market
Neuroendocrine Tumor Market- https://www.delveinsight.com/report-store/neuroendocrine-tumors-market
Nocturia Market- https://www.delveinsight.com/report-store/nocturia-market
Obstructive Sleep Apnea Market- https://www.delveinsight.com/report-store/obstructive-sleep-apnea-osa-market
Phototherapies For Psoriasis Market- https://www.delveinsight.com/report-store/phototherapy-devices-market
Plaque Modification Devices Market- https://www.delveinsight.com/report-store/plaque-modification-devices-market
Polycystic Ovarian Syndrome Market- https://www.delveinsight.com/report-store/polycystic-ovarian-syndrome-market
Primary Mediastinal Large B-cell Lymphoma Market- https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-market
Rosacea Market - https://www.delveinsight.com/report-store/rosacea-market
Sarcopenia Market- https://www.delveinsight.com/report-store/sarcopenia-market
Testicular Neoplasm Market- https://www.delveinsight.com/report-store/testicular-neoplasm-market
Type 1 Diabetes Market- https://www.delveinsight.com/report-store/type-1-diabetes-market
Vascular Access Devices Market- https://www.delveinsight.com/report-store/vascular-access-device-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Yash Bhardwaj
DelveInsight
+91 9650213330
email us here